ArticleParasites & vectors2025
Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the treatment and control of hookworm infections in dogs.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy of Credelio Quattro™ chewable tablets containing lotilaner, moxidectin, pyrantel, and praziquantel against Ctenocephalides felis and Rhipicephalus sanguineus infestations on dogs.Parasites & vectors · 2026Article
- Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs.Parasites & vectors · 2026Article
- Efficacy evaluation of a new oral chewable tablet containing fluralaner, moxidectin, and pyrantel (BRAVECTOParasites & vectors · 2026Article
- Field efficacy and safety evaluation of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel against gastrointestinal nematode infections in dogs in the USA.Parasites & vectors · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHookworms, specifically Ancylostoma caninum and Uncinaria stenocephala, have a clinical impact on the health of dogs, with A. caninum posing a zoonotic risk worldwide. The studies presented here were conducted to evaluate the efficacy of a novel, oral chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel (as pamoate salt) against fourth-stage larvae (L
methodsNine negatively controlled, masked, randomized laboratory studies evaluated the efficacy and non-interference of the drugs against various stages of A. caninum and U. stenocephala. In addition to one pilot study conducted against L
resultsAll dogs tolerated Credelio Quattro well. Efficacy of Credelio Quattro was ≥ 99.0% against L
conclusionsCredelio Quattro, a novel oral chewable tablet administered at the minimum effective dosages of 20 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5.0 mg/kg praziquantel, and 5.0 mg/kg pyrantel (as pamoate salt), was safe and effective for the treatment and control of L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.